MK-2682

MK-2682

Price: $ 165.00
Was: $ 200.00
Item: MK2682
Quantity
+
-
Previous Page
Add To Cart

MK-2682


Description: Methylester Kyseliny-anthranilove is an aryl hydrocarbon which modulates the androgen receptor. Liquid SARM
Concentration: 50mg per ml
Substantively: 24 hours
Organoleptic: Fruit initiation through to mint finish
Use: SARM and Anti-androgen; pushes androgen receptor activity to anabolic activity.
Active Ingredients: Methylester Kyseliny-anthranilove 50mg per ml
Application: 1ml daily with food in the morning.
Ingredients: Propylene Glycol, Methylester Kyseliny-anthranilove and flavour.
Elimination: Anthranilate esters have an average of 7-hour half-lives. Metabolised in liver.
Legal Status: Legal in Australia, food additive, FEMA

 

MK2682 is a non-steroidal compound designed to prevent muscle wasting, promote muscle growth and increase muscle and bone strength. After binding to receptors, MK2682 increases protein synthesis and anabolic activity, resulting in muscle hypertrophy and healing, mimicking the action of testosterone on muscles and joints. Unlike traditional androgenic steroids MK2682 does not lead to any of the associated side effects such as suppression of testosterone or increase in estrogen, making MK2682 desirable for this reason. Having anti-catabolic action’s, it prevents muscle wastage enabling the individual to hold lean muscle that is gained while trying to drop body fat. 

 

Key points:

• INCREASED STRENGTH
• INCREASE LEAN MUSCLE GAIN
• INCREASED BONE DENSITY
• INCREASED RECOVERY AND HEALING

 

Research Evidence & Efficacy


Roell, D., Rösler, T. W., Degen, S., Matusch, R., & Baniahmad, A. (2011). Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation. Chemical biology & drug design, 77(6), 450-459.
2 Negro-Vilar, A. (1999). Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. The Journal of Clinical Endocrinology & Metabolism, 84(10), 3459-3462.
3 Yin, D., Gao, W., Kearbey, J. D., Xu, H., Chung, K., He, Y., ... & Dalton, J. T. (2003). Pharmacodynamics of selective androgen receptor modulators. Journal of Pharmacology and Experimental Therapeutics, 304(3), 1334-1340.
4 https://tga-search.clients.funnelback.com/s/search.html?query=&collection=tga-artg
5 Gill, A. (2017). Standard for the uniform scheduling of medicines and poisons: The Poisons Standard 2017. Australian Government–Department of health and aging: Therapeutic Goods Administration, Canberra.

 

Research Evidence & Efficacy


6 Nickols, N. G., & Dervan, P. B. (2007). Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proceedings of the National Academy of Sciences, 104(25), 10418-10423.
7 Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. Journal of Biological Chemistry, 277(29), 26321-26326.
8 Sieber, P. R., Keiller, D. L., Kahnoski, R. J., Gallo, J., & Mcfadden, S. (2004). Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. The Journal of urology, 171(6), 2272-2276.
9 Schellhammer, P. F. (2002). An evaluation of bicalutamide in the treatment of prostate cancer. Expert opinion on pharmacotherapy, 3(9), 1313-1328.
10 Roell, D., Rösler, T. W., Degen, S., Matusch, R., & Baniahmad, A. (2011). Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation. Chemical biology & drug design, 77(6), 450-459.